| Project/Area Number |
20590572
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
NAGASAKA Takeshi Okayama University, 病院, 助教 (30452569)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KONDOU Yoshitaka 岡山大学, 病院, 医員 (50534765)
TANAKA Noriaki 岡山大学, 大学院・医歯薬学総合研究科, 教授 (10127566)
KOBAYASHI Naoya 岡山大学, 病院, 講師 (10325102)
MATSUBARA Nagahide 岡山大学, 医学部・歯学部附属病院, 講師 (70314672)
SASAMOTO Hiromi 岡山大学, 大学院・医歯薬学総合研究科, 外国人客員研究員 (10452567)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 腫瘍検査学 / 大腸癌 / メチル化 / スクリーニング / 便潜血反応 / 検便 / 癌 / ゲノム / トランスレーショナルリサーチ / 遺伝子 / 臨床 |
|---|
| Research Abstract |
The development of noninvasive screening tests is important to reduce mortality from gastrointestinal neoplasia. We sought to develop such a test by analysis of DNA methylation from exfoliated cancer cells in feces. We developed a novel strategy that uses single-step modification of DNA with sodium bisulfite and fluorescence polymerase chain reaction methodology to measure aberrant methylation in fecal DNA. Methylation was analyzed in 296 fecal samples obtained from a variety of patients, including 21 with gastric tumors, 152 with colorectal tumors, and 10 with non-neoplastic or inflammatory lesions in the gastrointestinal lumen. The assay successfully identified one or more methylated markers in fecal DNA from 57.1% of patients with gastric cancer, 75.0% of patients with colorectal cancer, and 44.4% of patients with advanced colorectal adenomas, but only 10.6% of subjects without neoplastic or active diseases. Methylation in fecal DNA is associated with the presence of gastrointestinal tumors relative to non-neoplastic conditions. Our novel fecal DNA methylation assay provides a possible means to noninvasively screen not only for colorectal tumors but also for gastric tumors.
|
